التفاصيل البيبلوغرافية
| العنوان: |
Avidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key Study. |
| المؤلفون: |
GATLIN, ALLISON (AUTHOR) |
| المصدر: |
Investors Business Daily. 3/30/2023, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*GROWTH stocks, *SMALL capitalization stocks, *INVESTORS, BLOOD-brain barrier, INTRACRANIAL hemorrhage, MUSCLE weakness |
| مستخلص: |
Avidity is testing its experimental drug in patients with myotonic dystrophy 1, an inherited disorder that causes progressive muscle weakness. A key study from B Avidity Biosciences b (RNA) remains on hold after a patient using its test-phase treatment experienced a "rarer than rare" side effect, leading RNA stock to plummet Thursday. Avidity Bio Crashes 17% After "Rarer Than Rare" Event Sidelines Key Study. [Extracted from the article] |
|
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
